The Global Antibiotic Research and Development Partnership (GARDP)

Global Antibiotic Research and Development Partnership

A not-for-profit research and development (R&D) organization established by WHO and DNDi to develop treatments for drug-resistant infections

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. Established by the WHO and the Drugs for Neglected Disease initiative (DNDi) in 2016, GARDP is a core element of WHO’s Global Action Plan on Antimicrobial Resistance.

GARDP was created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live and aims to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

GARDP is funded by a number of countries and foundations.

Collaboration agreements

WHO/DNDi Antimicrobial Project Collaboration Agreement (2016) (pdf)

583 KB

WHO/GARDP Collaboration Agreement (2018) (pdf)

2924 KB

Consultations

Throughout 2014 and 2015 WHO and DNDi held three technical consultations to review different options to foster the development of new antibacterial treatments that ultimately led to the creation of GARDP:

13 November 2015

Investing in the development of new antibiotics and their conservation: setting up a global antibiotic research and development partnership

8 – 9 December 2014

Joint WHO-DNDi meeting on fostering the development and rational use of new antibiotics

13 May 2014

WHO technical consultation on innovative models for new antibiotics' development and preservation

Activities

Coordinating R&D on antimicrobial resistance

The global burden of antimicrobial resistance requires new antibacterial treatments, especially for the most challenging resistant bacteria. WHO aims to set and coordinate ...